Bio-Rad Adds Rapid Bispecific Antibody Prototyping and Screening Services to Pioneer Antibody Discovery Platform
New Service Enables Identification of Bispecific Antibody Candidates Accelerating Drug Development.
Bio-Rad Outlines Its Advances Leveraging Droplet Digital PCR in Biopharma and Translational Research Sectors
Strategic Collaborations in Molecular Residual Disease Monitoring of Cancer and Product Launches in ddPCR Portfolio Advance Corporate Strategy in H1 2024
Bio-Rad Launches ChemiDoc Go Imaging System for Highly Sensitive Benchtop Gel and Western Blot Imaging
Compact System Uses CMOS Digital Imaging and Is Compatible with Chemiluminescence and Fluorescence Detection and Stain-Free Technology
Bio-Rad Launches Celselect Slides Version 2.0 to Advance Rare Cell and Circulating Tumor Cell Enrichment for Cancer Research
New Celselect Slides™ Design Increases Efficiency of Circulating Tumor Cell Capture from Liquid Biopsy Samples for Enumeration and Downstream Applications
Bio-Rad Extends Range of Anti-Biotherapeutic Antibodies to Accelerate Antibody Drug Development
Four New Anti-Idiotypic Antibodies and a New Anti-MMAE Antibody Range Support Bioanalytical Assay Development for Preclinical Research and Clinical Trials
Bio-Rad Launches ddSEQ™ Single-Cell 3’ RNA-Seq Kit for single cell gene expression
ddSEQ™ Single-Cell 3' RNA-Seq Kit and Omnition v1.1 Analysis Software Enable High-Quality and Affordable Single-Cell Transcription and Gene Expression to Support Molecular Biology, Oncology, and Drug Discovery Research
Bio-Rad Launches Three StarBright Red Dyes and Expands Range of Antibody Markers Conjugated to StarBright Violet Dyes to Enhance Immunology Research
Bio-Rad's Range of StarBright Dyes Conjugated to Highly Validated Antibodies Now Totals 32 Dyes, Providing Greater Choice and Flexibility for Conventional and Full-Spectrum Flow Cytometry in Immunology Research.
Bio-Rad Announces Collaboration Agreement with Oncocyte to Commercialize Transplant Monitoring with Droplet Digital PCR
Collaboration Aims to Provide Researchers Cutting-Edge Tools to Enable Transformational Monitoring of Key Biomarkers in Solid Tissue Transplants
Bio-Rad and Allegheny Health Network Cancer Institute Partner to Advance Personalized Monitoring of Solid Tumor Cancers with Droplet Digital PCR
Collaboration Aims to Grow Clinical Evidence Supporting the use of Bio-Rad’s ddPCR™ Technology for Molecular Residual Disease Monitoring of Patients across a Range of Solid Tumor Types
Bio-Rad Launches First Ultrasensitive Multiplexed Digital PCR Assay for Breast Cancer Mutation Detection in Clinical Research
Highly Sensitive and Multiplexed Assay for the Detection, Discrimination, and Quantification of Key Mutations in ESR1 Gene for Breast Cancer, Developed for Bio-Rad’s QX600™ Droplet Digital™ PCR System
Bio-Rad Launches Celselect Slides Validated Antibodies for Rare Cell and Circulating Tumor Cell Enumeration
Antibodies Validated for Use with Bio-Rad’s Celselect Slides™ Enumeration Stain Kits Enable Immunolstaining of Captured Circulating Tumor Cells in Liquid Biopsy Samples
Bio-Rad’s dd-Check STEC Solution Receives AOAC International Approval
The dd-Check STEC Solution is the First Droplet Digital™ PCR Method Approved by AOAC